Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals, Inc.verified

SLRX

Price:

$1.4599

Market Cap:

$2.10M

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea;...[Read more]

Industry

Biotechnology

IPO Date

2015-01-29

Stock Exchange

NASDAQ

Ticker

SLRX

The Enterprise Value as of November 2024 (TTM) for Salarius Pharmaceuticals, Inc. (SLRX) is -1168874.00

According to Salarius Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -1168874.00. This represents a change of -120.01% compared to the average of 5.84M of the last 4 quarters.

Salarius Pharmaceuticals, Inc. (SLRX) Historical Enterprise Value (quarterly & annually)

How has SLRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Salarius Pharmaceuticals, Inc. over the last ten years is 280.23M. The current -1168874.00 Enterprise Value has changed -141.71% with respect to the historical average. Over the past ten years (40 quarters), SLRX's Enterprise Value was at its highest in in the December 2014 quarter at 2.00B. The Enterprise Value was at its lowest in in the March 2024 quarter at -2185262.30.

Quarterly (TTM)
Annual

Average

280.23M

Median

99.19M

Minimum

-33854000.00

Maximum

1.33B

Salarius Pharmaceuticals, Inc. (SLRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Salarius Pharmaceuticals, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 153.37%

Maximum Annual Enterprise Value = 1.33B

Minimum Annual Increase = -4031.44%

Minimum Annual Enterprise Value = -33854000.00

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023-5608145.40-140.35%
202213.90M-89.69%
2021134.79M31.16%
2020102.77M7.49%
201995.61M153.37%
201837.73M-91.85%
2017462.73M-30.24%
2016663.30M-50.16%
20151.33B-4031.44%

Salarius Pharmaceuticals, Inc. (SLRX) Average Enterprise Value

How has SLRX Enterprise Value performed in the past?

The current Enterprise Value of Salarius Pharmaceuticals, Inc. (SLRX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

47.69M

5-year avg

68.29M

10-year avg

280.23M

Salarius Pharmaceuticals, Inc. (SLRX) Enterprise Value vs. Peers

How is SLRX’s Enterprise Value compared to its peers?

Salarius Pharmaceuticals, Inc.’s Enterprise Value is less than Akari Therapeutics, Plc (25.73M), greater than Axcella Health Inc. (-7493000.00), greater than Magenta Therapeutics, Inc. (-114170976.00), greater than Histogen Inc. (-3675930.00), less than Timber Pharmaceuticals, Inc. (-798315.00), less than Artelo Biosciences, Inc. (1.07M), less than Nutriband Inc. (57.20M), less than Aileron Therapeutics, Inc. (64.72M), less than First Wave BioPharma, Inc. (9.55M), less than SAB Biotherapeutics, Inc. (26.49M), less than Vaccinex, Inc. (8.95M), less than GeoVax Labs, Inc. (13.96M), less than Corvus Pharmaceuticals, Inc. (555.08M), less than Mereo BioPharma Group plc (537.63M), less than Affimed N.V. (49.39M), less than Pieris Pharmaceuticals, Inc. (2.69M), less than Artelo Biosciences, Inc. (1.07M), greater than Fresh Tracks Therapeutics, Inc. (-6447751.00),

Build a custom stock screener for Salarius Pharmaceuticals, Inc. (SLRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Salarius Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Salarius Pharmaceuticals, Inc. (SLRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Salarius Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Salarius Pharmaceuticals, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the 3-year average Enterprise Value for Salarius Pharmaceuticals, Inc. (SLRX)?

What is the 5-year average Enterprise Value for Salarius Pharmaceuticals, Inc. (SLRX)?

How does the current Enterprise Value for Salarius Pharmaceuticals, Inc. (SLRX) compare to its historical average?